PULM Pulmatrix, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1574235 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.0%
TTM net income YoY32.3%
TTM EPS YoY32.3%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-125.1%
Net margin-122.5%
FCF margin-142.4%
EBITDA margin-123.7%
Returns
ROE-71.0%
ROA-43.5%
ROIC (approx.)—
Asset turnover0.36x
Leverage & solvency
Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio5.3%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $3,000 |
| R&D expense | $1,000 | $2,000 | $3,000 | -$3,000 | $8,000 | $14,000 | $19,000 | $6,000 |
| SG&A expense | $1.22M | $1.04M | $1.29M | $911,000 | $858,000 | $1.53M | $1.83M | $1.95M |
| Operating income | -$1.22M | -$1.05M | -$1.29M | -$908,000 | -$866,000 | -$1.55M | -$1.85M | -$1.95M |
| Income tax | — | — | — | $0 | $0 | $0 | $0 | — |
| Net income | -$1.21M | -$1.04M | -$1.17M | -$928,000 | -$877,000 | -$1.55M | -$1.81M | -$1.99M |
| EBITDA | — | — | — | — | — | — | — | -$1.95M |
| EPS (basic) | -0.34 | -0.29 | -0.32 | — | -0.24 | -0.42 | -0.50 | — |
| EPS (diluted) | -0.34 | -0.29 | -0.32 | — | -0.24 | -0.42 | -0.50 | — |
| Weighted avg. shares (diluted) | 3.65M | 3.65M | 3.65M | — | 3.65M | 3.65M | 3.65M | — |
| Banking | ||||||||
| Net interest income | — | — | — | — | — | — | $53,000 | $73,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.40M | $2.17M | $3.32M | $4.09M | $4.79M | $5.83M | $7.71M | $9.52M |
| Receivables | — | — | — | — | — | — | $16,000 | — |
| Current assets | $2.36M | $3.24M | $4.49M | $4.13M | $4.97M | $6.14M | $8.04M | $9.92M |
| Total assets | $2.36M | $3.25M | $4.50M | $4.14M | $4.98M | $6.15M | $8.05M | $9.94M |
| Current liabilities | $1.02M | $689,000 | $905,000 | $329,000 | $249,000 | $548,000 | $903,000 | $929,000 |
| Total liabilities | $1.02M | $689,000 | $905,000 | $329,000 | $249,000 | $548,000 | $904,000 | $996,000 |
| Shareholders' equity | $1.35M | $2.56M | $3.59M | $3.81M | $4.73M | $5.60M | $7.15M | $8.95M |
| Shares outstanding | 3.65M | 3.65M | 3.65M | 3.65M | 3.65M | 3.65M | 3.65M | 3.65M |
| Cash flow statement | ||||||||
| Operating cash flow | -$770,000 | -$1.11M | -$1.07M | -$706,000 | -$1.03M | -$1.88M | -$1.81M | -$1.26M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$1.26M |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $0 | -$50,000 | $1.00M | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 |
| Stock-based compensation | $2,000 | $2,000 | $3,000 | $5,000 | $6,000 | $6,000 | $8,000 | $13,000 |
Free plan shows the latest 8 periods; Pro shows all 54 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.